
Igor Kutyaev/iStock via Getty Images
- CorMedix (NASDAQ:CRMD) shares rose about 20% premarket after it reported its preliminary fourth-quarter results.
- CorMedix reported preliminary net income of about $31 million for the fourth quarter of 2024 and about $43 million for fiscal 2024.
- Adjusted EBITDA for Q4 2024 is expected to exceed $12 million.